Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Versus Moderate Exposure Busulfan for Infants With SCID
NCT03619551Phase 2Active, not recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Oct 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of busulfan in severe combined immunodeficiency (SCID) (2 arms), sponsored by Center for International Blood and Marrow Transplant Research. Primary endpoint: Vaccine specific antibody response at 2 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
busulfan
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT03619551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619551.